| 1 |
35630083 | Sorafenib in Metastatic Papillary Thyroid Carcinoma with BRAF K601E Mutation on Liquid Biopsy: A Case Report and Literature Review. | 2022 May 17 |
2 |
| 2 |
33313992 | Drug repurposing using transcriptome sequencing and virtual drug screening in a patient with glioblastoma. | 2021 Jun |
1 |
| 3 |
33647741 | Design and synthesis of 4-anilinoquinazolines as Raf kinase inhibitors. Part 1. Selective B-Raf/B-RafV600E and potent EGFR/VEGFR2 inhibitory 4-(3-hydroxyanilino)-6-(1H-1,2,3-triazol-4-yl)quinazolines. | 2021 Apr |
1 |
| 4 |
34502061 | Establishment of Canine Transitional Cell Carcinoma Cell Lines Harboring BRAF V595E Mutation as a Therapeutic Target. | 2021 Aug 25 |
1 |
| 5 |
34691254 | Sorafenib treatment of metastatic melanoma with c-Kit aberration reduces tumor growth and promotes survival. | 2021 Dec |
1 |
| 6 |
32181767 | [vestigation of molecular factors determining BRAF-inhibitor sensitivity in solid tumors]. | 2020 Mar 17 |
1 |
| 7 |
32373219 | Targeted sequencing reveals the mutational landscape responsible for sorafenib therapy in advanced hepatocellular carcinoma. | 2020 |
1 |
| 8 |
32698374 | Inhibition of Methyltransferase DOT1L Sensitizes to Sorafenib Treatment AML Cells Irrespective of MLL-Rearrangements: A Novel Therapeutic Strategy for Pediatric AML. | 2020 Jul 20 |
1 |
| 9 |
30179868 | The BRAF Status May Predict Response to Sorafenib in Gastrointestinal Stromal Tumors Resistant to Imatinib, Sunitinib, and Regorafenib: Case Series and Review of the Literature. | 2019 |
4 |
| 10 |
30844744 | Sorafenib induces synergistic effect on inhibition of vemurafenib resistant melanoma growth. | 2019 Mar 1 |
1 |
| 11 |
31046582 | Renal Cell Carcinoma With Extensive Tumor Thrombus Into the Inferior Vena Cava and Right Atrium in a 70-Year-Old Man. | 2019 May-Jun |
1 |
| 12 |
31172191 | Histiocytic Sarcoma Following B-Lymphoblastic Leukemia/Lymphoma. | 2019 Sep 9 |
1 |
| 13 |
29631788 | Design and discovery of thioether and nicotinamide containing sorafenib analogues as multikinase inhibitors targeting B-Raf, B-RafV600E and VEGFR-2. | 2018 May 15 |
2 |
| 14 |
29881824 | Inhibition of insulin-like growth factor 1 receptor enhances the efficacy of sorafenib in inhibiting hepatocellular carcinoma cell growth and survival. | 2018 Jun |
1 |
| 15 |
30229251 | Structural insights and influence of V599 mutations on the overall dynamics of BRAF protein against its kinase domains. | 2018 Oct 15 |
2 |
| 16 |
28536078 | AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes. | 2017 Jul 15 |
4 |
| 17 |
28819429 | MAP2K1 Mutation in Colorectal Cancer Patients: Therapeutic Challenge Using Patient-Derived Tumor Cell Lines. | 2017 |
1 |
| 18 |
28978109 | Sorafenib inhibits therapeutic induction of necroptosis in acute leukemia cells. | 2017 Sep 15 |
1 |
| 19 |
26648069 | Biology, Epidemiology, Clinical Aspects of Hepatocellular Carcinoma and the Role of Sorafenib. | 2016 |
1 |
| 20 |
26786320 | (Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges. | 2016 Jan 19 |
2 |
| 21 |
27042004 | Selective use of sorafenib in the treatment of thyroid cancer. | 2016 |
1 |
| 22 |
27388325 | Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report. | 2016 Jul 7 |
3 |
| 23 |
27777009 | Design, synthesis and activity of novel sorafenib analogues bearing chalcone unit. | 2016 Nov 15 |
1 |
| 24 |
24833447 | Cutaneous Eyelid Neoplasms as a Toxicity of Vemurafenib Therapy. | 2015 Jul-Aug |
2 |
| 25 |
25605317 | Sorafenib for the treatment of thyroid cancer: an updated review. | 2015 Mar |
4 |
| 26 |
25879531 | Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status. | 2015 Mar 26 |
4 |
| 27 |
26067856 | Tyrosine Kinase Inhibitors as Potential Therapeutic Agents in the Treatment of Granulosa Cell Tumors of the Ovary. | 2015 Sep |
2 |
| 28 |
26200454 | Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort. | 2015 Oct |
1 |
| 29 |
26237499 | A significant response to sorafenib in a woman with advanced lung adenocarcinoma and a BRAF non-V600 mutation. | 2015 Oct |
3 |
| 30 |
26293246 | Limited Proteolysis Combined with Stable Isotope Labeling Reveals Conformational Changes in Protein (Pseudo)kinases upon Binding Small Molecules. | 2015 Oct 2 |
2 |
| 31 |
26299806 | Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells. | 2015 Sep 29 |
1 |
| 32 |
24399106 | Critical role of sorafenib exposure over time for its antitumor activity in thyroid cancer. | 2014 Jun |
1 |
| 33 |
24416138 | A phase I, dose-finding study of sorafenib in combination with gemcitabine and radiation therapy in patients with unresectable pancreatic adenocarcinoma: a Grupo Español Multidisciplinario en Cáncer Digestivo (GEMCAD) study. | 2014 |
1 |
| 34 |
24423208 | Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma. | 2014 Jan 14 |
1 |
| 35 |
24641301 | Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma. | 2014 Jul |
1 |
| 36 |
24803676 | Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. | 2014 Oct |
1 |
| 37 |
22941213 | Differential inhibitory effects of two Raf-targeting drugs, sorafenib and PLX4720, on the growth of multidrug-resistant cells. | 2013 Jan |
1 |
| 38 |
23494836 | Sorafenib in patients with refractory or recurrent multiple myeloma. | 2013 Dec |
1 |
| 39 |
23792568 | Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer. | 2013 Aug |
2 |
| 40 |
23804705 | Pharmacologic inhibition of MEK signaling prevents growth of canine hemangiosarcoma. | 2013 Sep |
1 |
| 41 |
24335681 | Vemurafenib treatment of BRAF V600E-mutated malignant peripheral nerve sheath tumor. | 2013 Dec 1 |
1 |
| 42 |
20803052 | Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium. | 2012 Feb |
1 |
| 43 |
21979753 | Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1). | 2012 Feb 10 |
1 |
| 44 |
22056813 | Dual inhibition of (V600E)BRAF and the PI3K/AKT/mTOR pathway cooperates to induce apoptosis in melanoma cells through a MEK-independent mechanism. | 2012 Jan 28 |
2 |
| 45 |
22096025 | Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. | 2012 Jan 1 |
1 |
| 46 |
22394203 | Sorafenib in melanoma. | 2012 Apr |
1 |
| 47 |
22431713 | Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway. | 2012 May |
1 |
| 48 |
22433711 | Synergistic antitumor efficacy of sequentially combined paclitaxel with sorafenib in vitro and in vivo NSCLC models harboring KRAS or BRAF mutations. | 2012 Sep 28 |
1 |
| 49 |
22479189 | LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients. | 2012 |
2 |
| 50 |
22649416 | Clinical outcome, role of BRAF(V600E), and molecular pathways in papillary thyroid microcarcinoma: is it an indolent cancer or an early stage of papillary thyroid cancer? | 2012 |
1 |